ACTI trade ideas
Lets discuss the latest clinical trial report Lund Sweden, July 31, 2018 –Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical Industries Ltd. The Phase 2 LEGATO-HD trial evaluating the safety and efficacy of laquinimod as a treatment in Huntington’s disease (HD) did not meet its primary endpoint of change from baseline after 12 months of treatment, as measured by the Unified Huntington’s Disease Rating Scale – Total Motor Score (UHDRS-TMS). The study’s secondary endpoint, reduction of brain atrophy (measured by caudate volume) was met. The safety results were similar to the expected event profile in this patient population.
prevalence Huntington disease= 2-10 / 100.000
Discussion: To date there is no cure for this degenerative disease, as published to the press the clinical trial currently at phase 2 did not meet the endpoint of changing the baseline for motor Score, this explains the profound falling of the price at that time (from 7 to 3 SEK). Now an important thought on this price action is the following. They managed to reduce the brain atrophy (i.e. the a decrements in the neural cellsize, or soma), which is in fact a much more reliable proof of work measurement than coining scores for the patients ability to control his/her movements , and in simple words means that the patient won't cure from this disease but he will deteriorate more slowly. Which is.... Progress right? En plus, the side effects are as expected. So, just from the research point of view this is not bad new, quite the contrary. For the price itself I believe it has a very tempting digit.
Happy trading
